



Mouse Anti-Ranibizumab monoclonal antibody, clone 21E23 (CABT-ZB241)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB241 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ranibizumab.
Specificity	The product is specific for Ranibizumab.
Target	Ranibizumab
Immunogen	Ranibizumab
Isotype	IgG1, κ
Source/Host	Mouse
Clone	21E23
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB240 - CABT-ZB241 Recommended Working Concentration: 0.01-0.1 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg

Buffer	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.
Keywords	Mouse monoclonal antibody to Lucentis; Lucentis; Ranibizumab; rhuFab V2; UNII-ZL1R02VT79

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Lucentis; Lucentis; Ranibizumab; rhuFab V2; UNII-ZL1R02VT79
-----------------	--